Longidaza in the form of a lyophilisate for solution
 Longidaza - pharmacological preparation on the basis of enzymes.

Structure and Composition

Longidaza includes lidazy (conjugate of hyaluronidase) activated with a copolymer of N - oxide poly-1, 4 - etilenpiperazina (which is similar to polioksidonija - preparation with immunomodulatory effects). Longidaza produced in the form of a lyophilisate for the preparation of a solution which can be administered both intramuscularly and subcutaneously.

The active substance - to the activity of hyaluronidase Longidaza 1500 IU or 3000 IU. Also included in the drug excipient - mannitol (respectively 15 or 20 mg).

Externally Longidaza is a porous hygroscopic mass of white (yellowish tint is allowed).

Produced Longidaza 5 ampoules (or vials) in contour plastic packaging in the box and instructions for use.

Pharmacological action Longidaza

This drug has enzymatic and proteolytic action Longidaza also has immunomodulatory, anti-inflammatory and antioxidant properties. Under the influence of hyaluronidase increases the elasticity of connective tissue, reduces swelling of tissues, flatten scars, increases range of motion in the joints, reduced adhesions. Besides Longidaza reduces inflammation in the acute phase, improves resistance to infection and improves the immune response.

According to the instructions Longidaza has no carcinogenic, teratogenic, mutagenic and allergenic effects. It is also known that the drug penetrates the blood-brain barrier.

After parenteral administration of the drug is very rapidly absorbed, the maximum concentration is determined after 25 minutes. The body Longidaza rapidly distributed. Withdrawal of the drug primarily by the kidneys. According to the instructions Longidaza Not accumulates in the body.


 Longidaza - drug has immunomodulatory effects
 Longidaza used in combination therapy for diseases which are accompanied by hyperplasia (overgrowth) connective tissue.

In pulmonology Longidaza used as part of a multi-component therapy for pulmonary fibrosis, tuberculosis, alveolitis, tuberculoma.

In gynecology Longidaza used for the treatment of adhesions in the pelvic cavity (after surgery, injury or inflammatory origin), chronic interstitial cystitis, as part of an integrated treatment of tubal-peritoneal infertility.

In surgery and orthopedics the drug is used in keloid and hypertrophic scars, contractures, adhesive process (abdomen), as well as long-term non-healing wounds (after injuries, burns) and trophic ulcers.

In dermatology Longidaza used to treat scleroderma.

Also, the medicament is used for increasing the bioavailability of other pharmacological agents.

Contraindications Longidaza

Hypersensitivity to the drug, malignant tumors, children's age (12 years), pregnancy.

Precautions Longidaza injections should be used for pulmonary bleeding, and signs of acute renal failure.

Dosing and Administration

According to the instructions Longidaza injected subcutaneously near the site of a lesion or scar tissue in a dose of 3000 IU, treatment is 5 - 15 administrations. The interval between injections Longidaza 3-10 days.

This drug can be administered intramuscularly, the duration of the course is the same. The route of administration and duration of therapy is determined by the physician depending on the disease, its severity and clinical manifestations, as well as the patient's age.

If necessary, the rate of re-treatment after 2-3 months.

To increase the bioavailability of other drugs administered in Longidaza dose of 1500 IU.

Prior to parenteral administration of the agents should be dissolved in 0, 25% or 0 to 5% solution of procaine (just one, 5-2 mL). If the patient has an intolerance procaine Longidaza then be dissolved with saline or water for injection. The prepared solution can not be stored.

Recommended regimens:

In diseases of the respiratory system Longidaza administered intramuscularly at a dose of 3000 IU, the course of 10 injections in 3-5 days. It is also possible long-term treatment with the drug (up to 1 year old) at a dose of 3000 IU after 10-14 days.

Gynecological diseases Longidaza also recommended administered intramuscularly at a dose of 3000 IU 3-5 days, the therapy is 5-15 injections.

When scleroderma (local) the drug is used at a dose of 3,000 - 4,500 IU once in 3 days. The course of treatment of 5-15 injections. The duration and dose are selected by the doctor individually.

In the treatment of keloid and hypertrophic scars, burns subcutaneous injections Longidaza carried out in the area near the scar. The dose of 3000 IU, it is recommended to inject 1-2 times per week, the course of 5 - 10 Introduction Longidaza.

When nonhealing wounds the medicament is administered intramuscularly at a dose of 1500 - 3000 IU once every five days, a course of therapy of 5-7 injections.

In the treatment of contractures, joint disease Longidaza injected intramuscularly at 3,000 IU, one - two times per week, the course of treatment is 7-15 injections.

In the treatment of adhesive disease Longidaza used as part of a treatment, it is administered by intramuscular injection of 3000 IU every 3-5 days, 7-15 recommended course of injections. Also, reviews Longidaza good use of electrophoresis.

If Longidaza appointed to increase the bioavailability of other drugs, it is recommended that administration of 1500 IU every three days, a course of 10 injections.

If a patient has symptoms of renal failure, it is recommended to use Longidaza not more than 1 time in 7 days.

Side effects Longidaza

In the opinion of Longidaza can cause soreness at the injection site. Rarely allergic reactions are noted. There are anecdotal reports of local reactions in the form of redness, swelling of tissues. In the opinion of Longidaza rarely causes such phenomena, and they are on their own within 48-72 hours.

Interaction with other drugs

According to the instructions Longidaza can be used in combination with other drugs (antibiotics, antifungals, antivirals, antihistamines, corticosteroids, cytotoxic drugs, bronchodilators).

Special instructions for use Longidaza

This drug should not be administered to the infected area (with acute inflammation), in an area with tumors.